These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35356254)

  • 61. Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy.
    Ni JY; Sun HL; Luo JH; Jiang XY; Chen D; Wang WD; Chen YT; Huang JH; Xu LF
    Cancer Manag Res; 2019; 11():9939-9950. PubMed ID: 32063720
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
    Wang K; Guo WX; Chen MS; Mao YL; Sun BC; Shi J; Zhang YJ; Meng Y; Yang YF; Cong WM; Wu MC; Lau WY; Cheng SQ
    Medicine (Baltimore); 2016 Mar; 95(11):e3015. PubMed ID: 26986115
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
    Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
    Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
    J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis.
    Zhang ZH; Hou SN; Yu JZ; Zhang W; Ma JQ; Yang MJ; Liu QX; Liu LX; Luo JJ; Qu XD; Yan ZP
    Front Oncol; 2022; 12():1086095. PubMed ID: 36741718
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined Chemoembolization and Radiotherapy Versus Chemoembolization Alone for Hepatocellular Carcinoma Invading the Hepatic Vein or Inferior Vena Cava.
    Alrashidi I; Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Gwon DI; Ko HK
    Cardiovasc Intervent Radiol; 2021 Jul; 44(7):1060-1069. PubMed ID: 33745071
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
    Li L; Cheng N; Huang X; Weng X; Jiao Y; Liu J; Guo W
    World J Surg Oncol; 2022 Feb; 20(1):30. PubMed ID: 35109883
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.
    Sun F; Liu KC; Ul Ain Q; Lu D; Zhou CZ; Xiao JK; Zhang XM; Zhang ZF; Cheng DL; He YS; Lv WF
    BMC Gastroenterol; 2024 Apr; 24(1):129. PubMed ID: 38589828
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Hu HT; Luo JP; Li HL; Guo CY; Yao QJ; Geng X; Jiang L
    Oncotarget; 2017 Apr; 8(17):29258-29268. PubMed ID: 28418927
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
    Li N; Yang P; Fang J
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102022. PubMed ID: 36089248
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.
    Peng TR; Wu TW; Wu CC; Chang SY; Chan CY; Hsu CS
    Tzu Chi Med J; 2022; 34(2):219-225. PubMed ID: 35465280
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control?
    Tamai T; Kumagai K; Sakae H; Onishi H; Tabu K; Tabu E; Muromachi K; Saishoji A; Oda K; Mawatari S; Moriuchi A; Sakurai K; Ido A
    Mol Clin Oncol; 2017 Dec; 7(6):1135-1141. PubMed ID: 29285389
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
    BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Bai T; Chen J; Xie ZB; Wu FX; Wang SD; Liu JJ; Li LQ
    Onco Targets Ther; 2016; 9():3841-8. PubMed ID: 27390524
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.